Axiom Catalyst

In this episode of the Axiom Catalyst Life Sciences Podcast, Jai Bains speaks with Dr. Gayathri Swaminath, VP of Cardiovascular at Pioneering Medicines, about the evolving role of pre-emptive medicine in cardiometabolic renal disease, with a focus on chronic kidney disease. From redefining early intervention to exploring the role of biomarkers, and multi-omics, this conversation dives into the science, system barriers, and future outlook for tackling CKD earlier and more effectively. Listen in to learn more!

Dan Simpson connected with Prof. Dave Pearce, Chair of the International Rare Diseases Research Consortium (IRDiRC) and professor of pediatric rare diseases. Prof. Pearce speaks passionately about the needs of rare disease patients around the world, and how the IRDiRC brings together funding agencies, companies, patient advocate groups, and other organization from approximately 80 countries to address patient care through a number of core initiatives.The IRDiRC is a global collaborative initiative launched in 2011 by the European Commission and the U.S. National Institutes of Health to tackle rare diseases through research and accomplish the vision to enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention. Dr. Pearce is an internationally recognized leader in a number of areas. He has published over 100 research papers on Batten disease, founded an international registry for rare diseases known as the Coordination of Rare Diseases at Sanford (CoRDS), and has served on numerous NIH review committees, rare disease advisory boards and has organized rare disease workshops.

Seona Lee and Dr Brandsema, pediatric neurologist at CHOP, discuss his firsthand specialist physician’s experience in treating rare disease patients – including the challenges, progress and hope for 2025. Listen in for some inspiring patient stories.Check out the work CHOP is doing to improve the lives of patients with Duchenne’s (DMD) here.

Go-to-Market Strategies: In this dynamic panel discussion moderated by the Managing Principal of Axiom Healthcare Strategies, experts dive into innovative strategies that are reshaping how pharma companies bring new therapies to market. From leveraging advanced data analytics to navigating regulatory pathways, the conversation covers key approaches to speed up launches and maximize impact for patients in oncology and rare diseases. To learn more about how we galvanize innovative product launches across oncology and rare diseases, reach out to our Managing Director, Jon Yoder, at jy@axiomhcs.com Catch the full conversation here: https://www.youtube.com/watch?v=_-oWLf_YeJo #HealthcareInnovation #ProductLaunch #LifeSciences #AxiomSummit #AxiomThinkTank

Best Foot Forward: Optimizing Clinical Trials during Today's Crossroads – Moderated by Giovanni Abbadessa of ModeX, this insightful panel features Lisa Mahnke of Nerviano Medical Sciences and Christiana Bardon of MPM. Discover how these leaders are optimizing clinical trials and evaluating asset strength in today's rapidly evolving healthcare landscape. To learn more about how we can help you develop your pre-clinical platform and prioritize effective clinical development plans, reach out to our Chief of Strategy, Anne Cherry, at ac@axiomhcs.com Watch the full discussion here: https://www.youtube.com/watch?v=pKMls_9UV80 #ClinicalTrials #HealthcareInnovation #AxiomSummit #MedicalResearch

Reimagining Clinical Trials – A thought-provoking panel moderated by the Managing Principal of Axiom Healthcare Strategies, featuring exertise among physicians and industry leaders: Hossein Borghaei, Corey Langer, Shruti Agrawal, Robert LaCaze, Alan Bash, and Nicholas Davies. Explore innovative approaches transforming traditional trial models. To learn more about our work supporting innovation in study designs, reach out to our Chief of Strategy, Anne Cherry, at ac@axiomhcs.com Watch the full panel here: https://youtu.be/Jf_4J9YZLI4?feature=shared #ClinicalTrials #FutureOfClinicalTrials #InnovatingResearch #ClinicalTrialsReimagined #AxiomSummit

Anne Cherry, Chief of Strategy at Axiom Healthcare Strategies, dives deep into identifying gaps and opportunities across the product development lifecycle. Learn how strategic insights are transforming patient outcomes and driving innovation. #AxiomCrossroads #BeBio #AxiomThinkTank

From the first new treatment in locally advanced cervical cancer in over a decade to buzz around exciting new drugs in development for ovarian and endometrial cancer, there have been many advances made in gynecologic cancer treatment in the past 12 months. In this Gynecologic Cancer Awareness Month special episode of Axiom Catalyst, Carlie Darefsky, Harish Venkatesan, Flannery Nania, and Luke Anderson talk through the challenges and hope for patients of gynecologic cancers. This podcast complements the infographics the Axiom team developed to highlight specific needs and challenges in cervical, ovarian, and endometrial cancers. #GynecologicCancer #GynAwarenessMonth2024 #AxiomThinkTank

Severe care disparities, barriers to diagnosis, harrowing patient stories, historically low survival… and yet… enduring hope for women worldwide.While significant progress has been made to address needs of women with gynecologic cancers, and the last 12 month have seen huge strides in advancing standards of care, key challenges remain including the inclusivity of clinical studies, asymmetric engagement and awareness across communities, and limited ability to tailor therapies, especially in later lines as care options dry up.In this this Gynecologic Cancer Awareness Month special episode of Axiom Catalyst, Dan Simpson, Carlie Darefsky, Harish Venkatesan and Flannery Nania talk through the challenges and hope for patients, as we look to the healthcare industry to raise the bar on health standards.This short podcast complements the specific infographics the Axiom team developed to highlight specific needs and challenges in cervical, ovarian and endometrial cancers respectively. Let’s keep raising awareness and saving lives! 🌸💪 #CervicalCancer #OverianCancer #EndometrialCancer #HealthcareAdvocacy #TogetherAgainstCancer #GynecologicCancer #GynAwarenessMonth2023 #AxiomThinkTank

May is ALS Awareness Month and this year Axiom is marking it with a dedicated podcast to help raise awareness about amyotrophic lateral sclerosis (ALS) also known as motor neuron disease. ALS is fatal with the average life expectancy after diagnosis being two to five years, although some patients may live for years or decades. There is still no known cure for ALS and current treatment options primarily target symptoms to improve quality of life, rather than stopping the disease progression. In this episode of Axiom Catalyst, Anna Graca is speaking with Dr Tim Williams from the Newcastle MND Care and Research Centre about how this devastating disease affects each individual differently and tremendous efforts of treating physicians and care coordinators to provide a personalised support to these patients and their families.

While significant therapeutic advances are underway for inherited blood disorders such as sickle cell disease, hemophilia and β-thalassemia, key challenges remain for the commercialization of these therapies, as well as disparities in access to these treatments and level of care received by patients. In this episode of Axiom Catalyst, we invited John James, CEO of Sickle Cell Society to discuss the impact of sickle celldisease on day-to-day lives of patients living in the UK, as well as current challenges in their clinical journey. We also explore the outreach work done by the Sickle Cell Society including key local initiatives such as the Hackney engagement project, and the translatory impact of their patient support work.

Join Justin, Rodrigo and Eriko’s discussion on bispecific antibody and CAR-T therapies. These innovative options are increasingly becoming available in late-line treatments for heme cancers. In this episode, we cover the advantages and disadvantages of bispecific and CAR-T treatments, emerging CRS considerations, as well as future directions for both modalities in how they pertain to myeloma and lymphoma treatment.